Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial

Study limitation reported by the research below: “Cataplexy improvement is mentioned in the interpretation but no specific cataplexy outcome numbers are provided in the abstract.”